Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 235-384-0 | CAS number: 12207-63-5
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
![](https://poisoncentres.echa.europa.eu/o/diss-blank-theme/images/factsheets/A-REACH/factsheet/print_toxicological-information.png)
Repeated dose toxicity: oral
Administrative data
- Endpoint:
- sub-chronic toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- supporting study
- Study period:
- not specified
- Reliability:
- 4 (not assignable)
- Rationale for reliability incl. deficiencies:
- documentation insufficient for assessment
- Remarks:
- poster only, no full description of methods and results
Cross-referenceopen allclose all
- Reason / purpose for cross-reference:
- reference to same study
Reference
- Endpoint:
- sub-chronic toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- supporting study
- Study period:
- not specified
- Reliability:
- 4 (not assignable)
- Rationale for reliability incl. deficiencies:
- documentation insufficient for assessment
- Remarks:
- poster only, no full description of methods and results
- Reason / purpose for cross-reference:
- reference to same study
- Reason / purpose for cross-reference:
- reference to same study
- Reason / purpose for cross-reference:
- reference to same study
- Qualifier:
- no guideline followed
- Principles of method if other than guideline:
- In this study, groups of 10 male and 10 female B6C3F1/N mice were exposed to sodium metavanadate at concentrations of 0, 31, 63, 125, 250, and 500 mg/L via drinking water for a duration of 13 weeks. The following parameters were investigated: mortality, body weight, water consumption, compound intake, haematology, and organ weights.
- GLP compliance:
- not specified
- Remarks:
- not specified in the publication
- Limit test:
- no
- Specific details on test material used for the study:
- not specified
- Species:
- mouse
- Strain:
- B6C3F1
- Details on species / strain selection:
- not specified
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- not specified
- Route of administration:
- oral: drinking water
- Details on route of administration:
- Exposure to vanadium may occur via ingestion.
- Vehicle:
- unchanged (no vehicle)
- Details on oral exposure:
- not specified
- Analytical verification of doses or concentrations:
- not specified
- Details on analytical verification of doses or concentrations:
- not specified
- Duration of treatment / exposure:
- 13 weeks
- Frequency of treatment:
- daily
- Dose / conc.:
- 31 mg/L drinking water
- Dose / conc.:
- 63 mg/L drinking water
- Dose / conc.:
- 125 mg/L drinking water
- Dose / conc.:
- 250 mg/L drinking water
- Dose / conc.:
- 500 mg/L drinking water
- No. of animals per sex per dose:
- 10 males / 10 females
- Control animals:
- yes
- Details on study design:
- - Dose selection rationale: drinking water concentrations were selected on 14-day data.
- Positive control:
- not specified
- Observations and examinations performed and frequency:
- CAGE SIDE OBSERVATIONS: Yes
- Cage side observations checked: survival
DETAILED CLINICAL OBSERVATIONS: Not specified
BODY WEIGHT: Yes
FOOD CONSUMPTION AND COMPOUND INTAKE: Not specified
FOOD EFFICIENCY:
- Body weight gain in kg/food consumption in kg per unit time X 100 calculated as time-weighted averages from the consumption and body weight gain data: Not specified
WATER CONSUMPTION AND COMPOUND INTAKE: Yes
OPHTHALMOSCOPIC EXAMINATION: Not specified
HAEMATOLOGY: Yes
CLINICAL CHEMISTRY: Not specified
URINALYSIS: Not specified
NEUROBEHAVIOURAL EXAMINATION: Not specified
IMMUNOLOGY: Not specified - Sacrifice and pathology:
- ORGAN WEIGHTS: Yes
HISTOPATHOLOGY: Yes (still under evaluation) - Statistics:
- mean and standard deviation
- Clinical signs:
- not specified
- Mortality:
- mortality observed, non-treatment-related
- Description (incidence):
- - one male mouse in the 500 mg/L group was removed from study in week 3, all other animals survived.
- Body weight and weight changes:
- effects observed, treatment-related
- Description (incidence and severity):
- - on day 91, male body weights were -26 % vs. controls in the 500 mg/L group, all others were within 11 % of controls; females were -23 % and -14 % vs. controls for 500 and 250 mg/L, respectively.
Please also refer to the field "Attached background material" below (Figure 7 in the attached document). - Food consumption and compound intake (if feeding study):
- not specified
- Food efficiency:
- not specified
- Water consumption and compound intake (if drinking water study):
- effects observed, treatment-related
- Description (incidence and severity):
- - there was a decrease in water consumption at 500 mg/L in males and females, resulting in less than dose proportional intake of sodium metavanadate
Please also refer to the field "Attached background material" below (Table 9 in the attached document). - Ophthalmological findings:
- not specified
- Haematological findings:
- effects observed, treatment-related
- Description (incidence and severity):
- - there was increase in erythrocytes (17 - 25 % at 500 mg/L) and reticulocytes (38 - 50 % at 500 mg/L) and small decrease in hematocrit and hemoglobin in males and females exposed to sodium metavanadate.
- Clinical biochemistry findings:
- not specified
- Urinalysis findings:
- not specified
- Behaviour (functional findings):
- not specified
- Immunological findings:
- not specified
- Organ weight findings including organ / body weight ratios:
- effects observed, treatment-related
- Description (incidence and severity):
- - thymus weights were lower in sodium metavanadate-exposed mice; 250 mg/L (male) and 500 mg/L
- Gross pathological findings:
- not specified
- Neuropathological findings:
- not specified
- Histopathological findings: non-neoplastic:
- not specified
- Histopathological findings: neoplastic:
- not specified
- Other effects:
- not specified
- Details on results:
- not specified
- Remarks on result:
- not determinable
- Critical effects observed:
- not specified
- Conclusions:
- In this study, groups of 10 male and 10 female B6C3F1/N mice were exposed to sodium metavanadate at concentrations of 0, 31, 63, 125, 250, and 500 mg/L via drinking water for a duration of 13 weeks. Sodium metavanadate in drinking water resulted in lower body weights and water consumption at 500 mg/L in adult mice. Mice exposed to higher concentrations of sodium metavanadate also had lower thymus weight. Lastly, mice exposed to higher (125, 150, 500 mg/L) concentrations of sodium metavanadate exhibited increase in erythrocytes and reticulocytes and decreases hematocrit and hemoglobin.
- Reason / purpose for cross-reference:
- reference to same study
Reference
- Endpoint:
- sub-chronic toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- supporting study
- Study period:
- not specified
- Reliability:
- 4 (not assignable)
- Rationale for reliability incl. deficiencies:
- documentation insufficient for assessment
- Remarks:
- poster only, no full description of methods and results
- Reason / purpose for cross-reference:
- reference to same study
- Reason / purpose for cross-reference:
- reference to same study
- Reason / purpose for cross-reference:
- reference to same study
- Qualifier:
- no guideline followed
- Principles of method if other than guideline:
- In this study, time-mated F0 Hsd:Sprague-Dawley rats were exposed to sodium metavanadate at concentrations of 0, 31, 63, 125, 250, and 500 mg/L via drinking water beginning on gestation day 6. Groups of male and female F1 animals were exposed during gestation, lactation and 13-weeks post-weaning (5 animals for biological sampling). The following parameters were investigated: mortality, body weight, water consumption, compund intake, and analysis of vanadium in plasma and urine.
- GLP compliance:
- not specified
- Remarks:
- not specified in the publication
- Limit test:
- no
- Specific details on test material used for the study:
- not specified
- Species:
- rat
- Strain:
- Sprague-Dawley
- Details on species / strain selection:
- not specified
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- not specified
- Route of administration:
- oral: drinking water
- Details on route of administration:
- Exposure to vanadium may occur via ingestion.
- Vehicle:
- unchanged (no vehicle)
- Details on oral exposure:
- not specified
- Analytical verification of doses or concentrations:
- not specified
- Details on analytical verification of doses or concentrations:
- not specified
- Duration of treatment / exposure:
- F0 group: gestation day 6 upto weaning of offspirng
F1 group: gestation day 6 upto weaning and 13- weeks post-weaning - Frequency of treatment:
- daily
- Dose / conc.:
- 31 mg/L drinking water
- Dose / conc.:
- 63 mg/L drinking water
- Dose / conc.:
- 125 mg/L drinking water
- Dose / conc.:
- 250 mg/L drinking water
- Dose / conc.:
- 500 mg/L drinking water
- No. of animals per sex per dose:
- F0 group: 16 females
F1 group: 15 males / 15 females - Control animals:
- yes
- Details on study design:
- - Dose selection rationale:
drinking water concentrations were selected on 14-day data.
Time-mated F0 rats were exposed to the test item via drinking water beginning on gestation day 6.
Groups of male and female F1 animals were exposed during gestation, lactation and 13-weeks post-weaning (5 animals for biological sampling). - Positive control:
- not specified
- Observations and examinations performed and frequency:
- CAGE SIDE OBSERVATIONS: Yes
- Cage side observations checked: surivival
DETAILED CLINICAL OBSERVATIONS: Not specified
BODY WEIGHT: Yes
- Time schedule for examinations: gestational, lactational F0 body weights, F1 body weights
FOOD CONSUMPTION AND COMPOUND INTAKE: Not specified
FOOD EFFICIENCY:
- Body weight gain in kg/food consumption in kg per unit time X 100 calculated as time-weighted averages from the consumption and body weight gain data: Not specified
WATER CONSUMPTION AND COMPOUND INTAKE: Yes
OPHTHALMOSCOPIC EXAMINATION: Not specified
CLINICAL PATHOLOGY: Yes (still under evaluation)
NEUROBEHAVIOURAL EXAMINATION: Not specified
IMMUNOLOGY: Not specified
OTHER:
1) Fertility, fecunditiy, pup surivival
2) measurement of vanadium concentration in plasma and urine
- at the end of the 13 week post weaning exposure period, 5 rats per sex per group, were placed in metabolism cages (24 hours) for collection of urine.
- after 24 hours, rats were euthanized and blood was collected.
- speciation of vanadium in biological fluids was not possible, thus total vanadium was measured.
- samples were thawed, processed by acid digestion with heat, spiked with internal standard (praseodymium) and diluted with DI H2O for analysis.
- samples were analysed using inductively-coupled plasma-mass spectrometry on a Thermo X-Series, ThermoFisher Scientific (Waltham, MA). - Sacrifice and pathology:
- ORGAN WEIGHTS: Yes
(still under evaluation)
HISTOPATHOLOGY: Yes (still under evaluation) - Statistics:
- mean and standard deviation
- Clinical signs:
- not specified
- Mortality:
- mortality observed, treatment-related
- Description (incidence):
- - moribundity resulted in removal of F0 animals during parturition and throughout lactation in the 250 and 500 mg/L groups.
- lower pup surivival was observed in 500 mg/L pups from postnatal day 1 - 10; surivival after postnatal day 10 was similar between exposed groups and controls.
Please also refer to the field "Attached background material" below (Table 4 in the attached document). - Body weight and weight changes:
- effects observed, treatment-related
- Description (incidence and severity):
- - there were lower body weights in dams during gestation and lactation that was proportional to sodium metavanadate exposure.
- body weight effects were only seen in pups at 500 mg/L.
- at the end of the study for F1 pups (13-weeks post weaning), lower body weights were seen in males at ≥ 125 mg/L (-10 to -20%) and in females at 500 mg/L (-12 %).
Please also refer to the field "Attached background material" below (Figure 4 in the attached document). - Food consumption and compound intake (if feeding study):
- not specified
- Food efficiency:
- not specified
- Water consumption and compound intake (if drinking water study):
- effects observed, treatment-related
- Description (incidence and severity):
- - there was lower water consumption in the 250 and 500 mg/L groups during gestation, lactation and post-weaning for male and female F1 offspring.
- due to lower water consumption, chemical consumption in the higher groups was slightly less than dose-proportional.
Please also refer to the field "Attached background material" below (Table 5 in the attached document). - Ophthalmological findings:
- not specified
- Haematological findings:
- not specified
- Clinical biochemistry findings:
- not specified
- Urinalysis findings:
- not specified
- Behaviour (functional findings):
- not specified
- Immunological findings:
- not specified
- Organ weight findings including organ / body weight ratios:
- not specified
- Gross pathological findings:
- not specified
- Neuropathological findings:
- not specified
- Histopathological findings: non-neoplastic:
- not specified
- Histopathological findings: neoplastic:
- not specified
- Other effects:
- not specified
- Details on results:
- MORTALITY:
- there was no impact on surivival during gestation.
Please also refer to the field "Attached background material" below (Table 4 in the attached document).
ANALYSIS FOR TOTAL VANADIUM IN PLSMA AND URINE:
Please also refer to the field "Attached background material" below (table 7 as well as figure 5 in the attached document). - Remarks on result:
- not determinable
- Critical effects observed:
- not specified
- Conclusions:
- In this study, time-mated F0 Hsd:Sprague-Dawley rats were exposed to sodium metavanadate at concentrations of 0, 31, 63, 125, 250, and 500 mg/L via drinking water beginning on gestation day 6. Groups of male and female F1 animals were exposed during gestation, lactation and 13-weeks post-weaning (5 animals for biological sampling). Dams/pups exposed to the substance at 250 and 500 mg/L in drinking water exhibited moribundity at birth, failure to thrive, and higher moribundity during lactation. Lower body weights were observed in dams during gestation and lactation, and in pups continuing until study termination. 13 weeks post-weaning.
- Reason / purpose for cross-reference:
- reference to same study
Reference
- Endpoint:
- sub-chronic toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- supporting study
- Study period:
- not specified
- Reliability:
- 4 (not assignable)
- Rationale for reliability incl. deficiencies:
- documentation insufficient for assessment
- Remarks:
- poster only, no full description of methods and results
- Reason / purpose for cross-reference:
- reference to same study
- Reason / purpose for cross-reference:
- reference to same study
- Reason / purpose for cross-reference:
- reference to same study
- Qualifier:
- no guideline followed
- Principles of method if other than guideline:
- In this study, time-mated F0 Hsd:Sprague-Dawley rats were exposed to vanadyl sulfate at concentrations of 0, 21, 42, 84, 168, and 335 mg/L via drinking water beginning on gestation day 6. Groups of male and female F1 animals were exposed during gestation, lactation and 13-weeks post-weaning (5 animals for biological sampling). The following parameters were investigated: mortality, body weight, water consumption, compund intake, and analysis of vanadium in plasma and urine.
- GLP compliance:
- not specified
- Remarks:
- not specified in the publication
- Limit test:
- no
- Specific details on test material used for the study:
- not specified
- Species:
- rat
- Strain:
- Sprague-Dawley
- Details on species / strain selection:
- not specified
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- not specified
- Route of administration:
- oral: drinking water
- Details on route of administration:
- Exposure to vanadium may occur via ingestion.
- Vehicle:
- unchanged (no vehicle)
- Details on oral exposure:
- not specified
- Analytical verification of doses or concentrations:
- not specified
- Details on analytical verification of doses or concentrations:
- not specified
- Duration of treatment / exposure:
- F0 group: gestation day 6 up to weaning of offspirng
F1 group: gestation day 6 up to weaning and 13- weeks post-weaning - Frequency of treatment:
- daily
- Dose / conc.:
- 21 mg/L drinking water
- Dose / conc.:
- 42 mg/L drinking water
- Dose / conc.:
- 84 mg/L drinking water
- Dose / conc.:
- 168 mg/L drinking water
- Dose / conc.:
- 335 mg/L drinking water
- No. of animals per sex per dose:
- F0 group: 16 females
F1 group: 15 males / 15 females - Control animals:
- yes
- Details on study design:
- - Dose selection rationale: drinking water concentrations were selected on 14-day data.
Time-mated F0 rats were exposed to the test item via drinking water beginning on gestation day 6.
Groups of male and female F1 animals were exposed during gestation, lactation and 13-weeks post-weaning (5 animals for biological sampling). - Positive control:
- not specified
- Observations and examinations performed and frequency:
- CAGE SIDE OBSERVATIONS: Yes
- Cage side observations checked: surivival
DETAILED CLINICAL OBSERVATIONS: Not specified
BODY WEIGHT: Yes
- Time schedule for examinations: gestational, lactational F0 body weights, F1 body weights
FOOD CONSUMPTION AND COMPOUND INTAKE: Not specified
FOOD EFFICIENCY:
- Body weight gain in kg/food consumption in kg per unit time X 100 calculated as time-weighted averages from the consumption and body weight gain data: Not specified
WATER CONSUMPTION AND COMPOUND INTAKE: Yes
OPHTHALMOSCOPIC EXAMINATION: Not specified
CLINICAL PATHOLOGY: Yes (still under evaluation)
NEUROBEHAVIOURAL EXAMINATION: Not specified
IMMUNOLOGY: Not specified
OTHER:
1) Fertility, fecunditiy, pup surivival
2) measurement of vanadium concentration in plasma and urine
- at the end of the 13 week post weaning exposure period, 5 rats per sex per group, were placed in metabolism cages (24 hours) for collection of urine.
- after 24 hours, rats were euthanized and blood was collected.
- speciation of vanadium in biological fluids was not possible, thus total vanadium was measured.
- samples were thawed, processed by acid digestion with heat, spiked with internal standard (praseodymium) and diluted with DI H2O for analysis.
- samples were analysed using inductively-coupled plasma-mass spectrometry on a Thermo X-Series, ThermoFisher Scientific (Waltham, MA). - Sacrifice and pathology:
- ORGAN WEIGHTS: Yes (still under evaluation)
HISTOPATHOLOGY: Yes (still under evaluation) - Statistics:
- mean and standard deviation
- Clinical signs:
- not specified
- Mortality:
- no mortality observed
- Body weight and weight changes:
- no effects observed
- Food consumption and compound intake (if feeding study):
- not specified
- Food efficiency:
- not specified
- Water consumption and compound intake (if drinking water study):
- effects observed, treatment-related
- Description (incidence and severity):
- - there was lower water consumption in the 168 and 335 mg/L groups during gestation and lactation (335 mg/L only); all others were within 10 % of controls.
- post-weaning, there was lower water consumption for F1 males ≥ 83.8 mg/L and females in the 335 mg/L group.
- due to lower water consumption, chemical consumption in the higher groups was slightly less than dose-proportional. - Ophthalmological findings:
- not specified
- Haematological findings:
- not specified
- Clinical biochemistry findings:
- not specified
- Urinalysis findings:
- not specified
- Behaviour (functional findings):
- not specified
- Immunological findings:
- not specified
- Organ weight findings including organ / body weight ratios:
- not specified
- Gross pathological findings:
- not specified
- Neuropathological findings:
- not specified
- Histopathological findings: non-neoplastic:
- not specified
- Histopathological findings: neoplastic:
- not specified
- Other effects:
- not specified
- Details on results:
- MORTALITY:
- there was no impact on F0 dam survival during gestation or lactation or F1 survival during lactation or post-weaning.
BODY WEIGHT AND WEIGHT CHANGES:
- there were no impacts on body weight during gestation or lactation for F0 females and no impact on F1 body weights during lactation or post-weaning.
- terminal F1 body weights were within 5 % of controls.
Please also refer to the field "Attached background material" below (Tables 2 and 3 in the attached document).
ANALYSIS FOR TOTAL VANADIUM IN PLSMA AND URINE:
Please also refer to the field "Attached background material" below (table 6 as well as figure 5 in the attached document). - Remarks on result:
- not determinable
- Critical effects observed:
- not specified
- Conclusions:
- In this study, time-mated F0 Hsd:Sprague-Dawley rats were exposed to vanadyl sulfate at concentrations of 0, 21, 42, 84, 168, and 335 mg/L via drinking water beginning on gestation day 6. Groups of male and female F1 animals were exposed during gestation, lactation and 13-weeks post-weaning (5 animals for biological sampling). Vanadyl sulfate, up to 335 mg/L in drinking water, was well tolerated in time-mated rats during gestation and lactation, and their pups during lactation and up to 13-weeks post weaning.
Data source
Reference
- Reference Type:
- publication
- Title:
- 3-month toxicity studies of tetravalent and pentavalent vanadium compounds in Hsd: Sprague-Dawley SD rats and B6C3F1/N mice via drinking water exposure
- Author:
- Roberts, G. et al.
- Year:
- 2 019
- Bibliographic source:
- Society of Toxicology, 2019 Annual Meeting, Abstract '2374, Poster Board #786
Materials and methods
Test guideline
- Qualifier:
- no guideline followed
- Principles of method if other than guideline:
- In this study, groups of 10 male and 10 female B6C3F1/N mice were exposed to vanadyl sulfate at concentrations of 0, 21, 42, 84, 168, and 335 mg/L via drinking water for a duration of 13 weeks. The following parameters were investigated: mortality, body weight, water consumption, compound intake, haematology, and organ weights.
- GLP compliance:
- not specified
- Remarks:
- not specified in the publication
- Limit test:
- no
Test material
- Reference substance name:
- Vanadium oxide sulphate
- EC Number:
- 248-652-7
- EC Name:
- Vanadium oxide sulphate
- Cas Number:
- 27774-13-6
- Molecular formula:
- VOSO4
- IUPAC Name:
- oxovanadium(2+) sulfate
- Test material form:
- not specified
- Details on test material:
- not specified
Constituent 1
- Specific details on test material used for the study:
- not specified
Test animals
- Species:
- mouse
- Strain:
- B6C3F1
- Details on species / strain selection:
- not specified
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- not specified
Administration / exposure
- Route of administration:
- oral: drinking water
- Details on route of administration:
- Exposure to vanadium may occur via ingestion.
- Vehicle:
- unchanged (no vehicle)
- Details on oral exposure:
- not specified
- Analytical verification of doses or concentrations:
- not specified
- Details on analytical verification of doses or concentrations:
- not specified
- Duration of treatment / exposure:
- 13 weeks
- Frequency of treatment:
- daily
Doses / concentrationsopen allclose all
- Dose / conc.:
- 21 mg/L drinking water
- Dose / conc.:
- 42 mg/L drinking water
- Dose / conc.:
- 84 mg/L drinking water
- Dose / conc.:
- 168 mg/L drinking water
- Dose / conc.:
- 335 mg/L drinking water
- No. of animals per sex per dose:
- 10 males / 10 females
- Control animals:
- yes
- Details on study design:
- - Dose selection rationale: drinking water concentrations were selected on 14-day data.
- Positive control:
- not specified
Examinations
- Observations and examinations performed and frequency:
- CAGE SIDE OBSERVATIONS: Yes
- Cage side observations checked: survival
DETAILED CLINICAL OBSERVATIONS: Not specified
BODY WEIGHT: Yes
FOOD CONSUMPTION AND COMPOUND INTAKE:
Not specified
FOOD EFFICIENCY:
- Body weight gain in kg/food consumption in kg per unit time X 100 calculated as time-weighted averages from the consumption and body weight gain data: Not specified
WATER CONSUMPTION AND COMPOUND INTAKE: Yes
OPHTHALMOSCOPIC EXAMINATION: Not specified
HAEMATOLOGY: Yes
CLINICAL CHEMISTRY: Not specified
URINALYSIS: Not specified
NEUROBEHAVIOURAL EXAMINATION: Not specified
IMMUNOLOGY: Not specified - Sacrifice and pathology:
- ORGAN WEIGHTS: Yes
HISTOPATHOLOGY: Yes (still under evaluation) - Statistics:
- mean and standard deviation
Results and discussion
Results of examinations
- Clinical signs:
- not specified
- Mortality:
- no mortality observed
- Description (incidence):
- - there was no impact on survival.
- Body weight and weight changes:
- no effects observed
- Food consumption and compound intake (if feeding study):
- not specified
- Food efficiency:
- not specified
- Water consumption and compound intake (if drinking water study):
- no effects observed
- Ophthalmological findings:
- not specified
- Haematological findings:
- no effects observed
- Clinical biochemistry findings:
- not specified
- Urinalysis findings:
- not specified
- Behaviour (functional findings):
- not specified
- Immunological findings:
- not specified
- Organ weight findings including organ / body weight ratios:
- no effects observed
- Gross pathological findings:
- not specified
- Neuropathological findings:
- not specified
- Histopathological findings: non-neoplastic:
- not specified
- Histopathological findings: neoplastic:
- not specified
- Other effects:
- not specified
- Details on results:
- BODY WEIGHTA AND WEIGHT CHANGES:
- terminal body weights were within 11 % of controls.
Please also refer to the field "Attached background material" below (Figure 6 in the attached document).
WATER CONSUMPTION AND COMPOUND INTAKE:
- there was a slight decrease in water consumption at 335 mg/L in males; no change in females.
Please also refer to the field "Attached background material" below (table 8 in the attached document).
HAEMATOLOGY:
- there were no changes in haematology considered related to vanadyl sulfate exposure.
ORGAN WEIGHTS:
- there were no changes in organ weights considered related to vanadyl sulfate exposure.
Effect levels
- Remarks on result:
- not determinable
Target system / organ toxicity
- Critical effects observed:
- not specified
Applicant's summary and conclusion
- Conclusions:
- In this study, groups of 10 male and 10 female B6C3F1/N mice were exposed to vanadyl sulfate at concentrations of 0, 21, 42, 84, 168, and 335 mg/L via drinking water for a duration of 13 weeks. Vanadyl sulfate, up to 335 mg/L in drinking water, was well tolerated in adult mice.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
![ECHA](/o/diss-blank-theme/images/factsheets/A-REACH/factsheet/echa_logo.png)